Scope review on Litesse polydextrose's impact on GLP-1 and other appetite-related parameters

Abstract

Litesse® polydextrose has been documented to enhance the body’s production of satiety hormones such as Glucagon-like peptide-1 (GLP-1). However, the combined results have not been reported concisely. This review aims to fill this gap. PubMed was searched for relevant articles in English. Seven preclinical and thirteen clinical articles were identified as relevant. Studies in rodents showed that Litesse leads to reduced serum triglycerides, lower insulin levels, and improved glycemic control, and enhances the effect of the type 2 diabetes drug sitagliptin on glucose tolerance and has the strongest impact on fasting glucose, likely via increased GLP-1. Further, feeding Litesse to mice reduced food intake and body weight. In humans, Litesse has been shown to increase postprandial GLP-1 release. This has been associated with a reduced daily energy intake and an improved post-prandial triglyceride response. A limitation is the relatively small size of the included studies. Litesse polydextrose has been shown to significantly affect gastrointestinal hormones such as GLP-1, PYY, and ghrelin. These hormonal changes are associated with improved appetite regulation, glucose control, insulin sensitivity, and triglyceride levels.